Strahlenther Onkol. 2021 Oct 20; doi: 10.1007/s00066-021-01860-8. Epub 2021 Oct 20.

Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Kerstin Clasen, Stefan Welz, Heidrun Faltin, Daniel Zips, Franziska Eckert

PMID: 34671818 DOI: 10.1007/s00066-021-01860-8

Abstract

PURPOSE: High Mobility Group Box 1 (HMGB1) protein has been described as a consensus marker for immunogenic cell death (ICD) in cancer. To personalize treatments, there is a need for biomarkers to adapt dose prescription, concomitant chemotherapy, and follow-up in radiation oncology. Thus, we investigated the levels of HMGB1 in plasma of patients with head and neck squamous cell carcinoma (HNSCC) during the course of radiochemotherapy and follow-up in correlation with oncologic outcome and clinical confounders.

METHODS: In our pilot study, 11 patients with advanced HNSCC were treated with definitive radiochemotherapy. Blood samples were taken weekly during treatment and frequently at follow-up visits. HMGB1 levels as well as routine laboratory values were measured and clinical information was collected including tumor volume, infections, toxicity, and follow-up data.

RESULTS: In total, 85 samples were analyzed. In eight patients, HMGB1 levels (baseline vs. last available sample during treatment) were increasing and in three patients HMGB1 values were decreasing toward the end of treatment. All three patients with decreasing values developed tumor recurrence. By contrast, no relapse occurred in patients that showed increasing HMGB1 levels during therapy. Moreover, a positive correlation of HMGB1 levels with tumor volumes, C‑reactive protein (CRP) levels, infections, and grade three toxicity (RTOG) was observed.

CONCLUSION: HMGB1 might be a promising marker to monitor ICD in HNSCC during the course of radiochemotherapy. However, HMGB1 seems to reflect complex and diverse immunogenic responses and potential confounders. Infections and treatment-associated toxicity should be considered when interpreting the dynamics of HMGB1.

© 2021. The Author(s).

Keywords: Biomarker; Head and neck cancer; Immunogenic cell death; Plasma; Radiotherapy

References

1. Linge A et al (2016) HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the German cancer consortium radiation oncology group (DKTK-ROG). Radiother Oncol 121(3):364–373 - PubMed
2. Baumann M et al (2016) Radiation oncology in the era of precision medicine. Nat Rev Cancer 16(4):234–249 - PubMed
3. Clasen K et al (2020) PET/MRI and genetic intrapatient heterogeneity in head and neck cancers. Strahlenther Onkol 196(6):542–551 - PubMed
4. Zwirner K et al (2019) Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D. Strahlenther Onkol 195(9):771–779 - PubMed
5. Stros M et al (2002) HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 277(9):7157–7164 - PubMed
6. Bianchi ME, Agresti A (2005) HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 15(5):496–506 - PubMed
7. Wang H et al (1999) HMG‑1 as a late mediator of endotoxin lethality in mice. Science 285(5425):248–251 - PubMed
8. Apetoh L et al (2007) Toll-like receptor 4‑dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059 - PubMed
9. Liao Y et al (2020) HMGB1 in radiotherapy: a two headed signal regulating tumor radiosensitivity and immunity. Onco Targets Ther 13:6859–6871 - PubMed
10. Andersson U et al (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192(4):565–570 - PubMed
11. Vaes RDW et al (2021) Biomarkers of radiotherapy-induced immunogenic cell death. Cells 10(4):930 - PubMed
12. Wu T et al (2016) HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget 7(31):50417–50427 - PubMed
13. Muth C et al (2016) Primary glioblastoma multiforme tumors and recurrence : comparative analysis of the danger signals HMGB1, HSP70, and calreticulin. Strahlenther Onkol 192(3):146–155 - PubMed
14. Chung HW et al (2009) Serum high mobility group box‑1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7:38 - PubMed
15. Chung HW et al (2012) Serum high mobility group box‑1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci 103(9):1714–1721 - PubMed
16. Qiu G et al (2014) Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol 31(12):316 - PubMed
17. Liikanen I et al (2015) Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. OncoImmunology 4(3):e989771 - PubMed
18. Galluzzi L, Kepp O, Kroemer G (2013) Immunogenic cell death in radiation therapy. OncoImmunology 2(10):e26536 - PubMed
19. Tesniere A et al (2010) Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4):482–491 - PubMed
20. Adkins I et al (2014) Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. OncoImmunology 3(12):e968434 - PubMed
21. Schildkopf P et al (2010) Application of hyperthermia in addition to ionizing irradiation fosters necrotic cell death and HMGB1 release of colorectal tumor cells. Biochem Biophys Res Commun 391(1):1014–1020 - PubMed
22. Kepp O et al (2014) Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 3(9):e955691 - PubMed
23. Galluzzi L et al (2020) Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 8(1):e337. https://doi.org/10.1136/jitc-2019-000337 - PubMed
24. Gehrmann M et al (2014) Hsp70—a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. Radiat Oncol 9:131 - PubMed
25. Schmid TE, Multhoff G (2012) Radiation-induced stress proteins—the role of heat shock proteins (HSP) in anti-tumor responses. Curr Med Chem 19(12):1765–1770 - PubMed
26. Yan H et al (2017) Clinical significance of serum dynamics of HSP90a level in esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Cancer Biomark 19(2):185–192 - PubMed
27. Eckert F et al (2018) Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. OncoImmunology 7(11):e1496881 - PubMed
28. Hoffmann E et al (2021) Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-021-03002-6 - PubMed
29. Yang H, Tracey KJ (2010) Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799(1–2):149–156 - PubMed
30. Klune JR et al (2008) HMGB1: endogenous danger signaling. Mol Med 14(7–8):476–484 - PubMed
31. Kocsis AK et al (2009) Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology 9(4):383–391 - PubMed
32. Angus DC et al (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35(4):1061–1067 - PubMed
33. Sapojnikova N et al (2014) Correlation between MMP‑9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome. Biochim Biophys Acta 1842(9):1379–1384 - PubMed
34. Wang C et al (2013) Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Care Res (Hoboken) 65(11):1828–1834 - PubMed
35. Wild CA et al (2012) HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 48(5):409–416 - PubMed
36. Mytilineos D et al (2020) Peripheral cytokine levels differ by HPV status and change treatment-dependently in patients with head and neck squamous cell carcinoma. Int J Mol Sci 21(17):5990. https://doi.org/10.3390/ijms21175990 - PubMed
37. Suzuki Y et al (2012) Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72(16):3967–3976 - PubMed

Publication Types

• Journal Article

Grant support

• 2447-0-0/fortüne / pate program of the medical faculty, eberhard karls university of tuebingen
• 70114187/deutsche krebshilfe